Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison

Background: The previously approved botulinum toxin and nowadays promising calcitonin gene-related peptide (CGRP) monoclonal antibody have shown efficacy for preventing chronic migraine (CM). However, there is no direct evidence for their relative effectiveness and safety. In this study, we conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jiajie, Zhang, Quanquan, Guo, Xiaoning, Liu, Wei, Xu, Chunyang, Hu, Xiaowei, Ni, Jianqiang, Lu, Haifeng, Zhao, Hongru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126691/
https://www.ncbi.nlm.nih.gov/pubmed/34012392
http://dx.doi.org/10.3389/fphar.2021.631204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126691/
https://www.ncbi.nlm.nih.gov/pubmed/34012392
http://dx.doi.org/10.3389/fphar.2021.631204

Ejemplares similares